HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Private Label Three-Day Yeast Infection Cream Offered By Taro

This article was originally published in The Tan Sheet

Executive Summary

Taro Pharmaceutical Industries' new drug application for clotrimazole 2% three-day cream was approved April 14 as a private label OTC vaginal yeast infection treatment identical to Schering-Plough's Gyne-Lotrimin 3 Cream. The product will appear on store shelves of major chains and mass merchandisers beginning in May.

You may also be interested in...

Direct-To-OTC Approvals, Line Extensions Replace Switches In 2000

Direct-to-OTC drug introductions and line extensions dominated the list of new product rollouts in 2000. The year marked the first time since 1993 that no Rx-to-OTC switches were approved, although FDA reviewed several switch candidates.

Taro Pharmaceuticals

Will market "several" topical dermatological and vaginal OTC products under an agreement with Schering-Plough that results from a previously announced joint research effort, Hawthorne, N.Y.-based Taro announces March 12. The two firms announced a joint R&D agreement on certain topicals in April 1998 ("The Tan Sheet" April 27, 1998, In Brief). Distribution of the products is expected to begin in the first half with additional products slated for introduction in the first quarter 2000. Taro will distribute the products under its own label and under various private label customers' OTC labels, the firm notes. Taro already markets topical 1% clotrimazole for athlete's foot and jock itch, which is comparable to Schering's Lotrimin AF. Clotrimazole also is the active ingredient in Schering vaginal yeast infection treatment Gyne-Lotrimin

Schering-Plough 2% Gyne-Lotrimin 3 Cream Will Be Launched In February

A new dosage form of Schering-Plough's vaginal yeast infection treatment Gyne-Lotrimin 3 with a 2% dose of the active ingredient clotrimazole will be introduced by the company in February. Schering plans no major advertising but will undertake FSIs.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts